Jeffrey S. Parkin

Array ( [id] => 13297303 [patent_doc_number] => 20180200188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Protease Cleavage Site Peptides as an HIV Vaccine [patent_app_type] => utility [patent_app_number] => 14/112622 [patent_app_country] => US [patent_app_date] => 2012-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14112622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330153 [patent_doc_number] => 20140056935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'PEPTIDE WHICH CAN INDUCE ANTIBODY CAPABLE OF RECOGNIZING STEREOSTRUCTURE OF HIV' [patent_app_type] => utility [patent_app_number] => 14/009757 [patent_app_country] => US [patent_app_date] => 2012-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14251 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14009757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8548782 [patent_doc_number] => 08323662 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2012-12-04 [patent_title] => 'Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein' [patent_app_type] => utility [patent_app_number] => 13/436472 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 27809 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13436472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14246199 [patent_doc_number] => 10273291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing [patent_app_type] => utility [patent_app_number] => 14/116710 [patent_app_country] => US [patent_app_date] => 2012-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 146 [patent_figures_cnt] => 121 [patent_no_of_words] => 22224 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14116710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9211662 [patent_doc_number] => 20140010839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-09 [patent_title] => 'METHOD OF SCREENING ANTIRETROVIRAL COMPOUNDS AND VACCINE' [patent_app_type] => utility [patent_app_number] => 14/006321 [patent_app_country] => US [patent_app_date] => 2012-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12659 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14006321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9273117 [patent_doc_number] => 08637044 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-28 [patent_title] => 'Method of generating an immune response in a subject using fusion proteins comprising CD4 minimal modules and HIV Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes' [patent_app_type] => utility [patent_app_number] => 13/427234 [patent_app_country] => US [patent_app_date] => 2012-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 24693 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13427234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8289331 [patent_doc_number] => 20120177657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-12 [patent_title] => 'FUSION PROTEINS COMPRISING CD4 MINIMAL MODULES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/426295 [patent_app_country] => US [patent_app_date] => 2012-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 27520 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13426295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9375979 [patent_doc_number] => 08680244 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-25 [patent_title] => 'Method for the production of antibodies that bind to multiple membrane spanning proteins' [patent_app_type] => utility [patent_app_number] => 13/421559 [patent_app_country] => US [patent_app_date] => 2012-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 33182 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13421559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9615767 [patent_doc_number] => 20140205624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'TETRAVALENT AND MIXED HEAD BIVALENT DENGUE VACCINE' [patent_app_type] => utility [patent_app_number] => 13/261724 [patent_app_country] => US [patent_app_date] => 2012-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5764 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13261724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8477115 [patent_doc_number] => 20120276522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'Methods and Compositions for Determining Virus Susceptibility to Integrase Inhibitors' [patent_app_type] => utility [patent_app_number] => 13/406283 [patent_app_country] => US [patent_app_date] => 2012-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 23801 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13406283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8393186 [patent_doc_number] => 20120231028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-13 [patent_title] => 'POLYVALENT VACCINE' [patent_app_type] => utility [patent_app_number] => 13/399963 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 9438 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13399963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8464685 [patent_doc_number] => 20120269851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'EXPRESSION CASSETTES ENDCODING HIV-1 SOUTH AFRICAN SUBTYPE C MODIFIED PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/399977 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 160 [patent_figures_cnt] => 160 [patent_no_of_words] => 45600 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13399977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277370 [patent_doc_number] => 09493847 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Molecular determinants in the HIV-1 envelope associated with enhanced ability to enter CXCR4-expressing cells' [patent_app_type] => utility [patent_app_number] => 13/370109 [patent_app_country] => US [patent_app_date] => 2012-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 27 [patent_no_of_words] => 19815 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 217 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13370109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8277289 [patent_doc_number] => 20120171160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-05 [patent_title] => 'EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/366730 [patent_app_country] => US [patent_app_date] => 2012-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8065 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13366730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634327 [patent_doc_number] => 20140212434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUSES' [patent_app_type] => utility [patent_app_number] => 13/983545 [patent_app_country] => US [patent_app_date] => 2012-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 24623 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13983545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441507 [patent_doc_number] => 20120258124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'ANTIGEN-ANTIBODY COMPLEXES AS HIV-1 VACCINES' [patent_app_type] => utility [patent_app_number] => 13/363313 [patent_app_country] => US [patent_app_date] => 2012-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 16272 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13363313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147845 [patent_doc_number] => 20130302368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'Advanced Prime and Boost Vaccine' [patent_app_type] => utility [patent_app_number] => 13/981173 [patent_app_country] => US [patent_app_date] => 2012-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3887 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13981173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8197139 [patent_doc_number] => 20120121636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-17 [patent_title] => 'Tat-Based Vaccine Compositions and Methods of Making and Using Same' [patent_app_type] => utility [patent_app_number] => 13/354986 [patent_app_country] => US [patent_app_date] => 2012-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9719 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20120121636.pdf [firstpage_image] =>[orig_patent_app_number] => 13354986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9965003 [patent_doc_number] => 09012618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures' [patent_app_type] => utility [patent_app_number] => 13/349917 [patent_app_country] => US [patent_app_date] => 2012-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 57 [patent_no_of_words] => 13334 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13349917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277039 [patent_doc_number] => 09493514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes' [patent_app_type] => utility [patent_app_number] => 13/978057 [patent_app_country] => US [patent_app_date] => 2012-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29588 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13978057 [rel_patent_id] =>[rel_patent_doc_number] =>)